Altimmune, Inc. (ALT) Stock Score, Valuation & Financial Research
Altimmune, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for ALT
Altimmune, Inc. currently has a Wall Street Score of 21/100. The stored market price is $3.27. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Altimmune, Inc. does
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
ALT financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $3.27
- Market capitalization:
- $635.9M
- Revenue:
- $31K
- Net income:
- $-91.8M
- Free cash flow:
- $-67.5M
- Cash:
- $63.0M
- Total debt:
- $35.7M
- EPS:
- -0.78
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $-67.5M, showing cash burn in the current stored period.
- The balance sheet shows $63.0M of cash versus $35.7M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.2 points: ALT decreased 0.2 points because Asset declined by 2 points.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ALT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.